![](/images/graphics-bg.png)
Temozolomide-Induced Myelodysplasia
Joint Authors
Natelson, Ethan A.
Pyatt, David
Source
Issue
Vol. 2010, Issue 2010 (31 Dec. 2010), pp.1-5, 5 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2010-03-04
Country of Publication
Egypt
No. of Pages
5
Main Subjects
Abstract EN
A patient who had received temozolomide (TMZ) as a single agent in treatment of malignant glioma developed therapy-induced myelodysplasia (T-MDS).
TMZ is an orally active imidazotetrazine which methylates guanine residues in DNA, ultimately causing single and double-strand DNA breaks leading to apoptotic cell death.
TMZ does not chemically cross-link DNA and is considered a nonclassical alkylating agent, similar in structure and activity to dacarbazine.
Observations on this patient, and on similarly treated others, suggest that the cumulative dose threshold (CDT) for TMZ that predisposes to T-MDS and which may potentially lead to acute myeloid leukemia (T-AML) is around 18000 to 20000 mg/sq m.
Although the incidence of T-MDS and the predisposing CDT of TMZ may differ from that of other potentially leukemogenic compounds currently and formerly used as chemotherapeutic agents, all alkylating agents, including TMZ, should be considered potentially leukemogenic when administered long term.
American Psychological Association (APA)
Natelson, Ethan A.& Pyatt, David. 2010. Temozolomide-Induced Myelodysplasia. Advances in Hematology،Vol. 2010, no. 2010, pp.1-5.
https://search.emarefa.net/detail/BIM-496601
Modern Language Association (MLA)
Natelson, Ethan A.& Pyatt, David. Temozolomide-Induced Myelodysplasia. Advances in Hematology No. 2010 (2010), pp.1-5.
https://search.emarefa.net/detail/BIM-496601
American Medical Association (AMA)
Natelson, Ethan A.& Pyatt, David. Temozolomide-Induced Myelodysplasia. Advances in Hematology. 2010. Vol. 2010, no. 2010, pp.1-5.
https://search.emarefa.net/detail/BIM-496601
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-496601